cost alternative to restasis
Imprimis Pharmaceuticals to Offer Compounded Cyclosporine Alternative to RestasisÂ® SAN DIEGO, Oct. 19, 2017 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today announced it is making compounded Cyclosporine-based formulations available for physicians to consider prescribing as customizable and potentially lower-cost alternatives to RestasisÂ®.